Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Anlotinib and Benmelstobart vs Surgery Alone for Localized Renal Cell Carcinoma
NCT07627464Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib, benmelstobart in renal cell carcinoma (RCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start May 2026; status: not yet recruiting.
02
Drugs
anlotinibbenmelstobart
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07627464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07627464.